Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses

Asahi Kasei Life Science covers a broad range of bioprocess products and services

Asahi Kasei Life Science begins operation

Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture

Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan

The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas

Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less

Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals

Asahi Kasei opens new Bioprocess Technical Center in China

The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics

Asahi Kasei Pharma files application for approval to manufacture and sell Cresemba Capsule

The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC